GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the Virtual Investor Lunch Break Series on July 17, 2024, at 12:00 PM ET. The event will feature a corporate overview and business outlook presented by CEO Marc Hertz, PhD.
Investors can join the live video webcast and participate in a Q&A session. The presentation will be available on the company's website, with a replay accessible for 90 days following the event. This presentation offers an opportunity for stakeholders to gain insights into GRI Bio's innovative pipeline and future prospects.
- None.
- None.
Live video webcast on Wednesday, July 17th at 12:00 PM ET
LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024 at 12:00 PM ET.
As part of the event, Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (gribio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
FAQ
When is GRI Bio (NASDAQ: GRI) participating in the Virtual Investor Lunch Break Series?
What will be discussed during GRI Bio's (NASDAQ: GRI) presentation at the Virtual Investor Lunch Break Series?
How can investors access GRI Bio's (NASDAQ: GRI) presentation at the Virtual Investor Lunch Break Series?
Will there be a Q&A session during GRI Bio's (NASDAQ: GRI) Virtual Investor Lunch Break Series presentation?
How long will the replay of GRI Bio's (NASDAQ: GRI) Virtual Investor Lunch Break Series presentation be available?
